FDMT Stoklara Genel Bakış Klinik aşamada bir biyoterapötik şirketi olan 4D Molecular Therapeutics, Inc. Hollanda ve Amerika Birleşik Devletleri'nde terapötik vektör evrimi platformunu kullanarak genetik ilaçlar geliştirmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
4D Molecular Therapeutics, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti 4D Molecular Therapeutics Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$4.55 52 Haftanın En Yüksek Seviyesi US$36.25 52 Haftanın En Düşük Seviyesi US$4.43 Beta 2.79 1 Aylık Değişim -4.41% 3 Aylık Değişim -43.27% 1 Yıllık Değişim -83.64% 3 Yıllık Değişim -69.63% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -88.77%
Son Haberler & Güncellemeler Daha fazla güncelleme görün
New minor risk - Share price stability Feb 03
New major risk - Revenue and earnings growth Jan 12
4D Molecular Therapeutics, Inc. Announces Strategically Focused Pipeline, Updated Phase 3 4Front Program Plans Jan 11
4Dmt Announces Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS Dec 17
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth Nov 24
Price target decreased by 8.7% to US$45.64 Nov 21
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 14
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure Oct 04
New major risk - Revenue and earnings growth Sep 23
New major risk - Share price stability Sep 20
4D Molecular Therapeutics Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4Front Phase 3 Program At 4D-150 Wet AMD Development Day Sep 19
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans Aug 10
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 09 4D Molecular Therapeutics, Inc. Announces Management Changes
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data Jul 19
4D Molecular Therapeutics, Inc. Announces Initial Interim 24-Week Data from the Population Extension Cohort of Its Phase 2 Clinical Trial Jul 17
Co-Founder notifies of intention to sell stock Jul 12
Co-Founder notifies of intention to sell stock Jun 27
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy Jun 24
4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference Jun 08
First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023) May 10
4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution Apr 29
New major risk - Shareholder dilution Apr 11
4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024 Apr 11
Insider notifies of intention to sell stock Apr 03
New major risk - Revenue and earnings growth Apr 01
Price target increased by 9.3% to US$54.75 Apr 01
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis Mar 29
Consensus revenue estimates decrease by 33%, EPS upgraded Mar 07
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 01
4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024 Feb 13
Chief Medical Officer exercised options and sold US$354k worth of stock Feb 10
New major risk - Shareholder dilution Feb 07 4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million. Feb 07
4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm Feb 06 4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Feb 06
New major risk - Share price stability Feb 06
Price target increased by 9.6% to US$37.00 Feb 05
4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150 Feb 05
Co-Founder notifies of intention to sell stock Jan 25
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Jan 25
Co-Founder notifies of intention to sell stock Jan 07
4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates Jan 05
4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD Dec 21
Co-Founder notifies of intention to sell stock Dec 18
Insufficient new directors Dec 01
Consensus revenue estimates increase by 96% Nov 16
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates Nov 12
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 10
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate Nov 08
4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC Nov 02
4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States Oct 31 4D Molecular Therapeutics, Inc. Announces Executive Changes
Price target decreased by 14% to US$33.50 Sep 12
4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD Sep 08
Consensus revenue estimates increase by 41% Aug 16
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 10
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023 Jul 30
Consensus revenue estimates increase by 163% Jul 13
4D Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting Jun 08
4Dmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society (Ecfs) 46Th Annual Meeting May 25
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation May 08
Price target increased by 8.3% to US$41.17 May 05
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 16
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema Feb 03
Price target increased by 8.1% to US$38.00 Jan 30
4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs Jan 11
4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs Jan 10
Co-Founder notifies of intention to sell stock Dec 22
Insider exercised options and sold US$85k worth of stock Dec 06
Price target increased to US$23.80 Nov 16
High number of new directors Nov 16
4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from On-Going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration Nov 15
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released November 14, 2022 Nov 11
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09
4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease At NACFC 2022 Nov 04
High number of new directors Nov 01
High number of new directors Oct 02
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate Sep 29
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer Sep 28
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M Aug 11
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell 2000 Growth Index Jun 26
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation Jun 11
Price target decreased to US$21.00 May 28
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Price target decreased to US$32.00 Apr 27
4D Molecular Therapeutics, Inc., Annual General Meeting, May 23, 2022 Apr 14
4D Molecular Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710 Apr 06
Consensus revenue estimates fall by 11% Apr 05
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 29 Hissedar Getirileri FDMT US Biotechs US Pazar 7D -25.9% -4.2% 0.2% 1Y -83.6% -3.0% 23.1%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: FDMT geçen yıl % -3 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: FDMT geçen yıl % 23.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is FDMT's price volatile compared to industry and market? FDMT volatility FDMT Average Weekly Movement 12.4% Biotechs Industry Average Movement 11.4% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
İstikrarlı Hisse Senedi Fiyatı: FDMT hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: FDMT 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında Klinik aşamada bir biyoterapötik şirketi olan 4D Molecular Therapeutics, Inc. Hollanda ve Amerika Birleşik Devletleri'nde terapötik vektör evrimi platformunu kullanarak genetik ilaçlar geliştirmektedir. Şirket, oftalmoloji, kardiyoloji ve pulmonoloji için üç terapötik alana odaklanan genetik ilaç ürün adaylarından oluşan bir portföy geliştirmektedir. Ürün hattı, yaşlılığa bağlı makula dejenerasyonunun tedavisi için faz 1/2 klinik çalışmada olan 4D-150'yi içermektedir; ve diyabetik makula ödeminin tedavisi için faz 1/2 klinik çalışmadadır.
Daha fazla göster 4D Molecular Therapeutics, Inc. Temel Bilgiler Özeti 4D Molecular Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? FDMT temel i̇stati̇sti̇kler Piyasa değeri US$211.72m Kazançlar(TTM ) -US$143.48m Gelir(TTM ) US$17.00k
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) FDMT gelir tablosu (TTM ) Gelir US$17.00k Gelir Maliyeti US$124.24m Brüt Kâr -US$124.22m Diğer Giderler US$19.26m Kazançlar -US$143.48m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -3.10 Brüt Marj -730,723.53% Net Kâr Marjı -844,000.00% Borç/Özkaynak Oranı 0%
FDMT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/12 23:25 Gün Sonu Hisse Fiyatı 2025/02/12 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları 4D Molecular Therapeutics, Inc. 14 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Huidong Wang Barclays Konstantinos Biliouris BMO Capital Markets Equity Research Daniel Giraldo BofA Global Research
Göster 11 daha fazla analist 
